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Abstract
Background: Hajdu-Cheney syndrome (HCS) (#OMIM 102500) is a rare, autosomal dominant condition that presents
in early childhood. It is caused by mutations in the terminal exon of NOTCH2, which encodes the transmembrane
NOTCH2 receptor. This pathway is involved in the coupled processes of bone formation and resorption. The skeletal
features of HCS include acro-osteolysis of the digits and osteoporosis commonly affecting vertebrae and long bones.
Fractures are a prominent feature and are associated with significant morbidity. There is no specific treatment, but with
both acro-osteolysis and generalized osteoporosis, it is possible that anti-resorptive treatment might be of benefit.
However, to date only a few case reports have evaluated the effectiveness of bisphosphonate treatment.
Methods: We describe the clinical features, treatment regimens and response to bisphosphonate treatment in 7 newly
described patients aged 6–39 with HCS, and pooled the data with that from 8 previously published cases (a total of 17
courses of treatment in 15 individuals).
Results: The mean lumbar spine bone mineral density (BMD) z-score before treatment was − 2.9 (SD 1.2). In 14 courses
of treatment (82%), there was an increase in BMD with bisphosphonate treatment, but the impact (in terms of change
in spinal BMD z-score) appeared to be less with advancing age (p = 0.01). There was no evidence that acro-osteolysis
was prevented.
Conclusions: Although individual response is variable and age-related, the data support a role for bisphosphonates in
preventing or treating spinal osteoporosis in HCS, but bone loss from the lumbar spine may be rapid after cessation.
Keywords: Bisphosphonates, Diseases, Genetic disorders, Human studies, Dual energy x-ray absorptiometry (DEXA)
Background
Hajdu-Cheney syndrome (HCS) (#OMIM 102500) is a
rare, autosomal dominant condition associated with a dis-
tinctive skeletal phenotype that includes both generalized
osteoporosis and localized acro-osteolysis [1, 2]. It pre-
sents in early childhood with characteristic dysmorphic
facial features and variable congenital abnormalities, such
as polycystic kidneys and heart disease [3–5]. Vertebral
and long bone fractures, a consequence of the osteopor-
osis, are common. Other skeletal findings include prema-
ture tooth loss, fibular deformities, scoliosis, joint
hyperlaxity, platybasia and basilar invagination [6]. HCS is
caused by mutations in the terminal exon of NOTCH2,
which encodes the transmembrane NOTCH2 receptor
[7]. Despite its dominant inheritance many cases do not
have a family history as the new mutation rate is high
(55%). Signaling through the NOTCH pathway is respon-
sible for cell differentiation and, specifically in the
precisely coupled processes of bone formation and bone
resorption [8]. In vitro studies suggest the NOTCH
pathway plays a role in committing mesenchymal stem
cells to the osteoblast lineage, thereby stimulating osteo-
clastogenesis [9].
Recurrent vertebral and non-vertebral fracture is a
major cause of morbidity in patients with HCS and the
neurological consequences of progressive platybasia are
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a significant contributor to the premature mortality
associated with the condition. Biochemical and histo-
morphometric evidence suggests that a high bone turn-
over state underlies the acro-osteolysis and spinal
osteoporosis [10, 11]. A recent histomorphometric study
has emphasized marked cortical osteopenia underlying
the liability to fracture [12].
A number of clinicians have trialed bisphosphonate
therapy in an attempt to retard acro-osteolysis and ver-
tebral bone loss. Only a few case reports of bisphospho-
nate treatment in HCS have been published [5, 12–14]
and with such a rare syndrome, the potential exists for
individual anecdote unduly to affect clinical decision-
making.
Here, we describe the outcome of bisphosphonate
treatment in seven additional patients with HCS, pooled
from different centers worldwide. Incorporating data
from the previously published case reports, we have
attempted to provide useful information on the effective-
ness of bisphosphonate treatment on acro-osteolysis and
osteoporosis in HCS.
Methods
Seven patients (5 female; median age 13 years, range 6–
39) were studied retrospectively. All carried a diagnosis
of HCS based on typical clinical and radiographic
features, and five had genetic confirmation. Three of the
seven were included in a report that described the pres-
ence of NOTCH2 mutations in the syndrome [7]. The
clinical indications leading to the decision to trial bis-
phosphonate were recurrent fracture and/or declining
bone mineral density (BMD), measured by dual-energy
X-ray absorptiometry (DXA). A variety of regimens were
used but bisphosphonate therapy was given for a mini-
mum of 1½ years. The treatment regimens for individual
patients are given in Table 1. One subject (Case 2) was
studied for two separate periods. She had treatment with
intravenous pamidronate aged 8 to 10, then had sequen-
tial BMD scans but no treatment until age 24 when she
was treated with intravenous zoledronate. We have also
reviewed data from eight other cases that have been
described in recent papers [5, 12–15].
Progression of acro-osteolysis was assessed from serial
radiographs of the hands and feet. BMD at the lumbar
spine was measured by dual-energy x-ray absorpti-
ometry. In each case the same machine was used for
initial and follow-up scans.
The densitometers used to measure BMD were as fol-
lows: GE Lunar Prodigy Advance (Lunar, Madison, WI,
USA; cases 1 and 4), Lunar DPX-L (Lunar, Madison, WI,
USA; cases 2 (aged 8) and 7), Hologic QDR-4500A
(Hologic, Waltham, MA, USA; case 3), GE Lunar Prod-
igy (Lunar, Madison, WI, USA; cases 2 (aged 24) and 5),
Hologic 2000 (Hologic, Waltham, MA, USA; case 6).
Because different densitometers were used and the
wide age range we report the BMD results as age-related
SD scores (z-scores), compared to the manufacturers’
normal ranges. Mean values were compared by paired t-
test and correlations by the Pearson method using IBM
SPSS Statistics (version 24.0 for Windows).
Results
Table 1 summarizes the clinical data, including the age
at starting treatment, the regimen given and its duration.
Six of the seven subjects had suffered fractures. The
mean z-score, measured after a median 4½ years’ bis-
phosphonate treatment, had increased from − 3.4 (SD 1.
2) to − 2.7 (1.4), but this difference was not statistically
significant (p = 0.158). The response however appeared
greater in the young. This was illustrated in subject 2,
whose spinal BMD z-score increased by 1.4 SD when
treated with pamidronate from 8 to 10 years of age, but
when treated with zoledronate at age 24 had only a 0.4
SD increase over a comparable time. In the interval be-
tween the two treatment periods, despite enjoying rea-
sonable health and reaching a normal height, her BMD
z-score declined markedly with a loss of 2.6 SD over
14 years (Fig. 1).
Table 2 (cases 8–15) lists data extracted from eight
other published reports [5, 12–15]. One subject (case 9
[12],) had two separate periods of bisphosphonate treat-
ment evaluated. Including these in the analysis, there
was a strong inverse relationship between change in
spine BMD z-score and the age at which treatment was
started (Pearson correlation coefficient − 0.624, p = 0.01;
Fig. 2). The only person > 15 years old whose z-score in-
creased by > 0.6 was a 57 year-old woman (case 15 [13],),
in whom accelerated bone loss post-menopause may have
been a factor.
Changes in acro-osteolysis in the hands were incon-
sistently reported. In 17 treatment periods (in 15 people)
no data was reported in six; in 7 cases there was no re-
sponse, in three cases progression was documented and
in only one case was progression said to have ‘slowed’.
There were no documented cases of improvement. Fig-
ure 3 illustrates the progressive radiographic change over
a twelve-year period in subject 7, who had the most pro-
longed course of bisphosphonate treatment. Loss of den-
tal bone and teeth was not systematically assessed in any
of the cases.
Discussion
HCS is a rare genetic condition, characterized by gener-
alized osteoporosis and focal bone loss (acro-osteolysis
and dental) [1, 2]. In the combined group we describe
75% of the patients over the age of 10 had vertebral frac-
tures. A number of previously published cases have sug-
gested that the generalized osteoporosis, as assessed by
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lumbar spine BMD, is to some degree responsive to
treatment using bisphosphonates [12, 15]. In the ex-
panded data set of 17 courses of treatment in 15 people,
there was some improvement in lumbar BMD in 14
(82%), but the responses were variable. Some of this
variability might be attributable to the use of regimens
of varying intensity and duration, but the age at the start
of treatment also seems to be important, with greater re-
sponses in the youngest patients.
It is to be expected that the growing skeleton will
respond best to bisphosphonates, which work in the
growing skeleton both by reducing resorption of the sec-
ondary spongiosa, so increasing trabecular bone mass,
and by inhibiting endosteal bone resorption during the
modelling of long bones, so increasing cortical thickness
[16]. It is noticeable from Fig. 2 that the response of
BMD to bisphosphonates in HCS becomes muted after
the age of 15 – well before the age that peak skeletal
mass is reached. Most forms of juvenile osteoporosis
arise from the failure of bone acquisition rather than ac-
celerated bone loss, but two of the cases illustrate that
bone loss after cessation of bisphosphonates can be very
rapid in HCS. As shown in Fig. 2, the teenage years and
early twenties of case 2 were marked by a substantial
loss of BMD (2.6 SD in 14 years), and case 10 (Table 2),
reported by Sakka et al. [12], lost 2.2 SD between the
ages of 14 and 19. It is not clear if this bone loss could
have been prevented with continued bisphosphonate
treatment, and clearly this is an important question for
future research. There is insufficient data to comment
on fracture rate or whether bisphosphonates might pre-
vent platybasia or the loss of dental bone that underlies
the characteristic premature tooth loss in HCS.
We found no evidence that bisphosphonate therapy
could promote healing of acro-osteolysis, and indeed
progression was documented in some subjects. This sug-
gests either a different mechanism underlies the focal
bone loss, that is not amenable to osteoclast inhibition,
or that there is inadequate bioavailability of bisphospho-
nate. The data are insufficient to know whether the rate
of progression would have been faster without bisphos-
phonate treatment.
Fig. 1 Sequential changes in lumbar spine z-score in one subject
(case 2), treated with pamidronate from 8 to 10 years of age, and
zoledronate at age 24. The increment in z-score was lower when
she was treated as an adult. Between these two treatment periods
her BMD z-score fell by 2.6 SD over 14 years
Table 2 Clinical features, treatment regimens and response to bisphosphonate treatment - previously published cases
Case [Ref] Gender - Age (yr)a NOTCH2
mutation
Fracture Details Treatment Regimen Scan interval
(years)
Lumbar spine z-score Acro-osteolysis
Before After Before After
8. [5] M 2 c.6909dup
p.I2304HfsX9
Metatarsals Pamidronate
3 mg/kg/3 m
5 −4.1 − 0.7 Hands and
feet
No response
9.b [12] M.6½ p.Val2221Glufs* Long bones Pamidronate
1 mg/kg/3
m - 1 yr
Alendronate
35–70 mg - 5½ yr
6 −1.9 + 0.1 Hands and
feet
No response
M.17½ Zoledronate
5 mg × 1 age 17½
2½ −2.1 −1.7 Hands and
feet
Not recorded
10 [15]. F.10 Clinical Vertebral, metatarsal,
metacarpal
Pamidronate
4 mg/kg/3 m
2 −3.4 −0.7 Hands and
feet
Not recorded
11 [12]. M.10½ Clinical Vertebral, long bones Alendronate
35–70 mg/wk
4 − 0.5 + 2.8 Hands and
feet
Slowed
progression
12 [12]. F.15 p.Leu2301* Vertebral, long bones Zoledronate
50 μg/kg/6 m
3 −3.4 −2.4 Hands and
feet
No response
13 [12]. M.15½ pGln2263* Vertebral Zoledronate
50 μg/kg/6 m
1½ −0.8 − 0.7 Hands and
feet
Not recorded
14 [14]. F 41 c.6854delA
p.Q2285RfsX9
None Zoledronate
5 mg/yr
3 −2.5 −2.6 Hands Worse
15 [13]. F 57 Clinical Vertebral compression Alendronate
10 mg/day
4 −3.6 −2.7 Hands No response
aAt start of treatment, bPatient studied in two separate periods
*translation termination codon (stop codon)
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Adami et al. reported the effects of treatment with an-
other inhibitor of bone resorption, the RANKL-inhibitor
denosumab, in a 33 year-old woman with HCS who had
previously been treated with bisphosphonates and stron-
tium [17]. The change in lumbar spine BMD (+ 0.5 SD
over 2 years) was much in line with the results presented
in this paper and acro-osteolysis progressed. McKiernan
described the effects of combination therapy with an
anabolic agent as well as an anti-resorptive agent in a
39 year-old woman with HCS treated for 2 years with
both teriparatide and pamidronate. Her lumbar spine
BMD z-score improved from − 7.1 to − 5.5, but over the
same period steroid treatment (prescribed for a different
indication) was withdrawn. There was no change in
acro-osteolysis [14]. For comparison, data from these
two cases has been included in Fig. 2.
Given that the molecular basis of HCS is now known
[7], and that bisphosphonate therapy in is essentially em-
pirical, opportunities to explore treatment strategies
around signaling through NOTCH2 should be consid-
ered. In HCS, mutations in the terminal exon of
NOTCH2 lead to the creation of a stop codon upstream
of the PEST (proline (P), glutamic acid (E), serine (S),
and (T) threonine) domain, responsible for ubiquitina-
tion and degradation of NOTCH, leading to a persist-
ence of NOTCH2 signaling [7, 16]. In murine models,
this has been shown to increase bone resorption due to
a direct effect on osteoclast precursors and due to an
increase in RANKL by the osteoblast increasing osteo-
clastogenesis [17].
NOTCH-ligand interactions result in release of the
NOTCH intracellular domain (NICD) which translocates
to the nucleus and forms a protein complex with recom-
bination signal-binding protein for immunoglobulin κJ
region (Rbpjκ) and Mastermind-like to induce transcrip-
tion of downstream effectors of this signaling pathway
(transcription factors of the hairy enhancer of split
(HES) gene family, HES and HEY) [18]. Interruption of
this pathway promises a more targeted approach to
Fig. 2 Scatterplot showing the negative correlation between change
(Δ) in lumbar spine BMD z-score with bisphosphonate treatment in
relation to the age at which treatment was started (17 courses of
treatment in 15 individuals). Pearson correlation coefficient − 0.624
(p = 0.01). The new cases (from Table 1) are shown by green circles
and the cases previously described in the literature (Table 2) are shown
by red squares. The light blue triangle indicates the response in the
patient described by Adami et al. [17] who was treated with
denosumab for 2 years; the dark blue triangle the patient
described by McKiernan [18] who was treated with both
pamidronate and teriparatide for two years
Fig. 3 Progression of acro-osteolysis despite treatment with bisphosphonates. Radiographs of the right index finger of subject 7, taken over
12 years. The timing of bisphosphonate treatment is indicated
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treatment. Possible drug targets in the pathway include
inhibitors of the enzyme complexes that cleave the
NOTCH extra- and intracellular domains (alpha and
gamma secretase, respectively) or antibodies to the
NOTCH2 receptor itself. An antibody to NOTCH2 has
been shown to reverse the osteopenic phenotype in HCS
mutant mice [19]. NOTCH signaling dysfunction is also
implicated in the pathogenesis of a number of
hematological and solid tumor malignancies. Gamma
secretase inhibitors are in clinical trials in such malig-
nancies, and although not specific to NOTCH2, these
results could potentially inform novel therapeutic ap-
proaches in HCS [20].
Conclusions
We have described the responses of acro-osteolysis and
spinal BMD to treatment with bisphosphonates in a new
cohort of patients with Hajdu-Cheney syndrome, and
reviewed the previously published literature. Our data
suggest that bisphosphonate treatment does not arrest
acro-osteolysis, but spinal BMD is improved. The great-
est effect is seen in younger patients and bone loss can
be rapid when bisphosphonates are discontinued.
Although this is the largest group described to date, the
numbers are still small, as is typical with such rare dis-
eases, and larger numbers are required to confirm the
efficacy of bisphosphonate treatment. Better therapeutic
options may be available in the future with increased
understanding of the molecular pathogenesis of the con-
dition and the growing experience of gamma secretase
inhibitors in clinical oncology.
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